Literature
首页医源资料库医学文档库心血管相关

  Catheter Ablation for the Cure of Atrial Fibrillation Study
Presented at
American College of Cardiology
Scientific Sessions 2005
Presented by Dr. Emanuele Bertaglia
CACAF Study
Endpoint:
Total absence of atrial tachyarrhythmia recurrence during 12 month follow-up
CACAF Study
Presented at ACC Scientific Sessions 2005
137 patients with paroxysmal or persistent atrial fibrillation
intolerant to or who have already failed ≥2 antiarrhythmic drugs.
First atrial fibrillation diagnosis at least 6 months prior to enrollment.
Randomized
Catheter Ablation and Antiarrhythmic Drugs
n=68
Antiarrhythmic Drugs
n=69
Presented at ACC Scientific Sessions 2005
The primary endpoint of atrial arrhythmia free survival was higher in the ablation group compared with the control group (p<0.001), with 44% of the ablation group and 91% of the control group having at least 1 AF recurrence.
Procedure duration was 193 minutes in the ablation group, with fluoroscopy time of 25 minutes.
All patients in the ablation group had right isthmus block and 30% had left isthmus block.
Major complications were similar in the two treatment groups (5.9% for ablation group and 5.8% for control group).
At Least 1 AF Recurrence
CACAF Study
p<0.001
Among patients with paroxysmal or persistent atrial fibrillation who have already failed antiarrhythmic drugs, use of catheter ablation was associated with a reduction in atrial fibrillation recurrence at 1 year compared with antiarrhythmic drug therapy alone.
Prior studies of ablation in atrial fibrillation have been primarily non-randomized or single center, and success has been defined only in terms of symptom relief. The present study is the first multicenter, randomized trial to show a benefit of preventing atrial fibrillation recurrence with a single session of catheter ablation.
CACAF Study: Summary
Presented at ACC Scientific Sessions 2005
医学百科App—中西医基础知识学习工具
  • 相关内容
  • 近期更新
  • 热文榜
    •
    医学百科App—健康测试工具